Business description: Concord Biotech Limited

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.

Number of employees: 1,571

Sales by Activity: Concord Biotech Limited

Fiscal Period: March 2021 (INR) 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR)

Manufacturing and trading in pharmaceutical products

616.4Cr 712.93Cr 853.17Cr 1.02TCr 1.2TCr

Geographical breakdown of sales: Concord Biotech Limited

Fiscal Period: March 2021 (INR) 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR)

India

252.65Cr 337.41Cr 432.13Cr 534.21Cr 661.83Cr

Others

204.5Cr 244.07Cr 273.78Cr 374.75Cr 400.28Cr

America

159.25Cr 131.45Cr 147.25Cr 107.98Cr 137.97Cr

Executive Committee: Concord Biotech Limited

Manager TitleAgeSince
Chief Executive Officer - 01/09/2011
Director of Finance/CFO - 18/12/2025
Corporate Officer/Principal 73 14/02/2011
Compliance Officer - 11/02/2026
Corporate Officer/Principal - -

Composition of the Board of Directors: Concord Biotech Limited

Director TitleAgeSince
Director/Board Member 55 30/06/2008
Chairman 73 14/02/2011
Director/Board Member 62 15/12/2003
Director/Board Member 81 31/01/2017
Director/Board Member 73 14/06/2022
Director/Board Member 57 31/01/2017
Director/Board Member 66 24/05/2022
Director/Board Member 79 14/06/2022
Director/Board Member - 01/09/2011

Shareholders: Concord Biotech Limited

NameEquities%Valuation
28.84 %
3,01,69,524 28.84 % 323 M ₹
9.547 %
99,87,636 9.547 % 107 M ₹
Aryavir Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 90 M ₹
Aryaman Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 90 M ₹
Nishtha Jhunjhunwala Discretionary Trust
8.029 %
83,99,732 8.029 % 90 M ₹

Company details: Concord Biotech Limited

Concord Biotech Ltd.

B-Wing, Mondeal Heights

380015, Ahmedabad

+91 79 6813 8700

http://www.concordbiotech.com
address Concord Biotech Limited(CONCORDBIO)

Biopharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
+4.27%+2.56%-37.88% - 116.64Cr
+0.61%+0.23%+33.28%-8.44% 7.66TCr
+2.01%-4.04%+93.62%+200.57% 5.8TCr
-0.93%+60.10%+60.10%+60.10% 5.06TCr
-0.31%-1.48%-42.71%-54.57% 4.73TCr
+0.76%+2.53%+49.52%-39.31% 2.58TCr
-1.76%+5.42%+117.36%-62.69% 2.17TCr
+2.62%+1.82%+68.05%+30.43% 1.9TCr
+1.84%+3.64%+60.08%+55.24% 1.55TCr
-0.98%+2.90%+126.60%+410.65% 1.5TCr
Average +0.81%+0.45%+52.80%+65.78% 3.31TCr
Weighted average by Cap. +0.46%+0.03%+51.12%+50.61%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1,081.70INR
Average target price
1,414.17INR
Spread / Average Target
+30.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock
  4. Company Concord Biotech Limited